The FDA De Novo medical device pathway, patents and anticompetition

Nat Biotechnol. 2020 Sep;38(9):1028-1029. doi: 10.1038/s41587-020-0653-6.

Jacob S Sherkow^{1

2

3}, Mateo Aboy^{4

5}

¹ College of Law, University of Illinois at Urbana-Champaign, Champaign, IL, USA. jsherkow@illinois.edu.
² Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Champaign, IL, USA. jsherkow@illinois.edu.
³ Center for Advanced Studies in Biomedical Innovation Law, University of Copenhagen Faculty of Law, Copenhagen, Denmark. jsherkow@illinois.edu.
⁴ Centre for Law Medicine and Life Sciences, University of Cambridge, Cambridge, UK. ma608@cam.ac.uk.
⁵ Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard Law School, Cambridge, MA, USA. ma608@cam.ac.uk.

No abstract available

MeSH terms